Experience with pioglitasone (actos) in the treatment of polycystic ovary syndrome
https://doi.org/10.14341/probl200551115-18
Abstract
The paper presents the authors 'data obtained from examinations of 1 7 patients aged 15 to 36 years who had polycystic ovary syndrome (PCOS) and insulin resistance before and after therapy with pioglitasone in a daily dose of 30 mg, regardless of the time of a meal, for 3 months. The study was undertaken to examine the effects of pioglitasone on carbohydrate and lipid metabolic parameters, as well as on the hormonal parameters of ovarian function and on the basic clinical manifestations in patients with PCOS. Elimination of insulin resistance with the sensitizers of the action of insulin, such as pioglitasone, contributes to the normalization of reproductive function in most patients with PCOS and insulin resistance.
About the Authors
I I DedovEndocrinology Research Centre
Russian Federation
A A Pishchulin
Endocrinology Research Centre
Russian Federation
I S Yarovaya
Endocrinology Research Centre
Russian Federation
I G Akmayev
Endocrinology Research Centre
Russian Federation
References
1. Анциферов М.Б., Григорян О.Р., Чернова Т.О.//Пробл. репродукции. -2001. -№ 1. -С. 49-55.
2. Балаболкин М.И., Клебанова Е. М., Креминская В. М. Дифференциальная диагностика и лечение эндокринных заболеваний (руководство). -М., 2002.
3. Зыкова Т.А. Синдром подикистозных яичников -новые аспекты старой проблемы. -Архангельск, 2001.
4. Карпова Е.А., Пшцулин А.А.//Тезисы IX Российского национального конгресса "Человек и лекарство". -М., 2002. -С. 196.
5. Arlt W., Auchus R.J., Miller W.L. // J. Biol. Chem. - 2001. - Vol.276. - P. 16767-16771. Bonora £., Targher G., Alberche M. et al. // Diabetes Care. - 2000. - Vol.23, № 1. - P. 57-72.
6. DunaifA., Xia J., Book C. et al.//J. Clin. Invest. -1995. -Vol.96. -P. 801-810.
7. Dunaif A. et al.//J. Clin. Endocrinol. Metab. -1996. -Vol.81. -P. 3299.
8. Dunaif A.//Endocrinol. Metab. Clin. N. Am. -1999. -Vol.28. -P. 341-359.
9. Ehrmann D.A., Cavaghan М.К., Imperial J. et al.//J. Clin. Endocrinol. Metab. -1997. -Vol.82, № 2. -P. 524-530.
10. Ehrmann D.A., Schneider D.J., Sobel В.Е. et al.//J. Clin. Endocrinol. Metab. -1997. -Vol.82. -P. 2108-2112.
11. Matthews D.R., Hosker J.P., Rudenski A.S. еt al.//Diabeto-logia. -1985. -Vol.28. -P. 412-419.
12. Ming Li, Youngren J.F., Dunaif A. et al.//J. Clin. Endocrinol. Metab. -2002. -Vol.87. -P. 4088-4093.
13. Reaven G.M., Laws A. Insulin Resistance. The Metabolic
14. Sundrome X. -Clifton, 1999. -P. 373.
15. Sanaka M., Iwamoto Y.//Nippon Rinsho. -2000. -Vol.58, № 2. -P. 465-470.
Review
For citations:
Dedov I.I., Pishchulin A.A., Yarovaya I.S., Akmayev I.G. Experience with pioglitasone (actos) in the treatment of polycystic ovary syndrome. Problems of Endocrinology. 2005;51(1):15-18. (In Russ.) https://doi.org/10.14341/probl200551115-18
Views:
4736
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
